| 产品介绍 |
MK-1775 (AZD1775) is a highly potent, selective and orally bioavailable Wee1 kinase inhibitor with IC50 of 5.2 nM. It abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin etc. and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. At tolerated doses, MK-1775 treatment leads to xenograft tumor growth inhibition or regression. It inhibits Wee1 in H3K36me3-deficient cells results in RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. MK-1775 can regresse H3K36me3-deficient tumor xenografts too. Right now MK-1775 is in phase I/II clinical trials for various cancers.
CAS号：955365-80-7
分子式：C27H32N8O2
分子量：500.61
MDL：MFCD17215200
纯度：≥99.5% (TLC)
外观：粉末
溶解性：溶于DMSO (125 mg/mL)
作用靶点：Wee1;
作用通路：Cell Cycle/DNA Damage;
产品描述：阿达色替 (Adavosertib) 是一种有效的 Wee1 抑制剂，IC50 值为 5.2 nM。
|
